Exercise and tirzepatide for better weight and health
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests whether combining a weight-loss medication called tirzepatide (also known as Mounjaro) with a supervised exercise program helps people lose weight and improve their overall health. You'll be in the study for about four months, and you'll get support and monitoring.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 30 and 65 years old.
- Your body mass index (BMI) should be 27–29.9 with an extra heart-related risk factor, or 30–40.
- You are not taking insulin or other diabetes medicines, and your blood sugar is below a certain level.
- You have no history of serious heart problems like heart attack, stroke, or heart failure.
- You have not used weight loss medication in the past year.
- You get approval from your primary care doctor before starting the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether tirzepatide, a medication that helps with weight loss and blood sugar control, can improve the ability to exercise and daily function in people who have heart failure with reduced pumping strength and are overweight or obese.
This study tests whether the medicine tirzepatide can help adults who are overweight or obese and have congenital heart disease (a heart condition present from birth) lose weight safely. The medicine may also improve heart health and metabolism. It is for people who have already tried diet and exercise for at least a year without much weight loss.
This trial tests if the weight loss medication tirzepatide can help young adults (18–40) with obesity and high blood pressure lower their blood pressure. It compares standard care to weight loss with tirzepatide.
This study looks at how well the medicine tirzepatide works in real life for adults who are overweight (BMI 30 or more) and have prediabetes or type 2 diabetes. It aims to see if the medicine helps control blood sugar and weight, and it's important that you have had a recent eye exam before starting.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
This study looks at whether adding a structured exercise program to the weight-loss medication tirzepatide can improve muscle health and physical function in people who are overweight or obese. Participants will exercise while taking their usual medication, and the researchers will measure muscle quality and strength.
Hear when a new Obesity & Overweight trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.